COMPASS Pathways plc (CMPS)

NASDAQ: CMPS · Real-Time Price · USD

11.90

-0.05 (-0.42%)

At close: Oct 2, 2026, 4:00 PM EDT

11.84

-0.06 (-0.50%)

After-hours: Oct 2, 2026, 7:55 PM EDT

Market Cap	1.65B +197.7%
Revenue (ttm)	n/a
Net Income	-394.19M
EPS	-3.61
Shares Out	138.48M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,664,368
Open	12.00
Previous Close	11.95
Day's Range	11.63 - 12.07
52-Week Range	4.88 - 15.87
Beta	2.56
Analysts	Strong Buy
Price Target	23.75 (+99.58%)
Est. Earnings	Nov 3, 2026

About CMPS

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in L... [Read more]

Industry Medical Care Facilities

Sector Healthcare

IPO Date Sep 18, 2020

Employees 156

Stock Exchange Nasdaq

Ticker Symbol CMPS

Website https://compasspathways.com

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 16 analysts, the average rating for CMPS stock is "Strong Buy." The 12-month stock price target is $23.75, which is an increase of 99.58% from the latest price.

Price Target

$23.75

(99.58% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, ...

2 days ago - Business Wire

Compass Pathways names Kelley Boucher as Chief People Officer

Compass Pathways (CMPS) announced the appointment of Kelley Boucher as Chief People Officer, effective September 30. This appointment strengthens the Compass executive team as the company continues to...

4 days ago - TheFly

Compass Pathways Appoints Kelley Boucher as Chief People Officer

4 days ago - Business Wire

COMPASS Pathways Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit

Phase III data for COMP360 in treatment-resistant depression show durable, incremental benefits with additional doses and a strong safety profile. NDA filing is on track for Q4, with launch readiness by year-end and broad commercial site preparedness. Most states will reschedule rapidly post-approval, and robust training, reimbursement, and support systems are in place.

11 days ago - Transcripts

COMPASS Pathways Transcript: Deutsche Bank 2026 Healthcare Summit

COMP360 is on track for FDA submission in Q4 2026 and potential launch in H1 2027 for TRD, with strong clinical results, positive payer feedback, and robust commercial preparation. The product offers a differentiated profile versus SPRAVATO, and expansion into PTSD and other neuropsychiatric indications is underway.

17 days ago - Transcripts

COMPASS Pathways Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

A novel psychedelic therapy for treatment-resistant depression is nearing FDA approval, with rapid and durable efficacy shown in phase III trials and a launch targeted for the first half of 2027. Strong payer interest, robust infrastructure, and a large unmet patient need support significant market potential, while a major PTSD program is also advancing.

18 days ago - Transcripts

Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026

18 days ago - Business Wire

COMPASS Pathways Transcript: H.C. Wainwright 28th Annual Global Investment Conference

COMP360 showed rapid, durable efficacy in TRD with just one to four annual doses, and open-label data support sustained benefits up to a year. Regulatory review is accelerated, with launch readiness by end of 2026 and commercial launch expected in early 2027. The PTSD program is advancing and may represent an even larger opportunity.

19 days ago - Transcripts

Compass Pathways Launches ‘Change the Tune in TRD' in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

19 days ago - Business Wire

Strata Mental Health Solutions awarded training grant by Compass Pathways

Strata Mental Health Solutions announced it has been awarded one of the five U.S. HCP training grants awarded by Compass Pathways (CMPS) to develop U.S. health care provider training programs…

23 days ago - TheFly

Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360

ATLANTA--(BUSINESS WIRE)--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been ...

23 days ago - Business Wire

Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training

New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider ...

24 days ago - PRNewsWire

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

24 days ago - Business Wire

Compass Pathways to Participate in Investor Conferences the Week of September 14th

24 days ago - Business Wire

Compass Pathways Forecast: Breakout Could Target $22.51–$25.51

CMPS is testing a breakout after positive Phase 3 data, with a close above $15.40 potentially opening the way toward $22.51–$25.51.

25 days ago - FXEmpire

COMPASS Pathways Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

COMP360 is progressing through FDA review for TRD, with launch targeted for early 2027 and a differentiated profile versus existing therapies. Commercial planning leverages new reimbursement codes, streamlined site logistics, and patient support, while expansion into PTSD addresses a significant unmet need.

25 days ago - Transcripts

Compass Pathways reports 52-week results from Phase 3 COMP005 trial

Compass Pathways (CMPS) announced the topline 52-week results (Part C) from its Phase 3 COMP005 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression...

25 days ago - TheFly

Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year

25 days ago - Business Wire

Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026

26 days ago - Business Wire

Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 20...

4 weeks ago - Business Wire

Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026